公募基金方面，本期较上一期持股增加的公募基金共计1个，即格林碳中和主题混合A，持股增加占比 小幅上涨。本期较上一季度持股减少的公募基金共计6个，主要包括华夏上证科创板50成份ETF、易方 达上证科创板50ETF、博时上证科创板新材料ETF、南方上证科创板新材料ETF、招商中证商品指数基 金等，持股减少占比达0.49%。本期较上一季未再披露的公募基金共计161个，主要包括南方中证 500ETF、科创ETF、广发科创50ETF、科创板ETF、国联安科创ETF等。 2025年4月30日，凯赛生物(688065.SH)发布2025年第一季报。截至2025年4月30日，共有16个机构投资 者披露持有凯赛生物A股股份，合计持股量达5.13亿股，占凯赛生物总股本的71.17%。其中，前十大机 构投资者包括上海曜修生物技术合伙企业(有限合伙)、山西潞安矿业(集团)有限责任公司、Cathay Industrial Biotech Ltd.、山西科技创新城投资开发有限公司、HBM Healthcare Investments (Cayman) Ltd.、天津四通陇彤缘企业管理合伙企业(有限合伙)、四川天府银行股份有限公司营业部、 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Views - The company's Q1 2025 performance met expectations, with total revenue of 776 million yuan, a year-on-year increase of 13% and a quarter-on-quarter increase of 4%. The net profit attributable to the parent company was 137 million yuan, reflecting a year-on-year growth of 30% [6][7] - The long-chain dicarboxylic acid business is experiencing steady growth, particularly with the ramp-up of sebacic acid, which has enhanced profitability. The company has increased sales efforts and is expanding its market share in new products [6] - Significant progress has been made in promoting bio-based polyamide modified and continuous fiber composite materials, with commercial orders expected to materialize [6] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3,539 million yuan, with a year-on-year growth rate of 19.6%. The net profit attributable to the parent company is forecasted to be 648 million yuan, representing a growth rate of 32.4% [6][7] - The gross profit margin for Q1 2025 was 33.63%, showing an increase of 4.95 percentage points year-on-year and 5.22 percentage points quarter-on-quarter [6] - The company’s return on equity (ROE) is projected to improve from 0.8% in Q1 2025 to 5.4% by 2027 [6]

Core Viewpoint - The article highlights the financial performance of Kasei Biotech in Q1 2025, showcasing significant growth in revenue and net profit, primarily driven by the sales of long-chain dicarboxylic acids [2][4]. Financial Performance - Kasei Biotech reported a revenue of 776 million yuan in Q1 2025, representing a year-on-year increase of 13.3% [2][3]. - The net profit attributable to shareholders reached 137 million yuan, up 30.1% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains was 135 million yuan, reflecting a 31.4% increase year-on-year [2][3]. - Research and development expenses amounted to 60.55 million yuan, marking a 35.21% increase from the previous year [2][3]. Product and Market Insights - The growth in net profit is attributed to the increased sales volume and gross profit from the series of long-chain dicarboxylic acids [4]. - Long-chain dicarboxylic acids (LCDA) are gaining traction in various applications, including the production of high-performance materials and pharmaceuticals [5]. - Kasei Biotech is positioned as a leading global supplier of bio-manufactured long-chain dicarboxylic acids, capitalizing on the market shift from traditional chemical methods to more sustainable production [5]. Capacity and Future Outlook - Kasei Biotech has a production capacity of 115,000 tons per year for bio-manufactured long-chain dicarboxylic acids and other related products [7]. - The company has successfully ramped up production of new products, such as dodecanedioic acid, contributing to significant revenue growth [6].

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月26日，第三届中国（安徽）科交会专项活动——合成生物平台建设和科技招商专项活动在合肥举办。 在重大项目签约环节，合肥高新区管委会、芜湖三山经开区管委会等地方政府单位与上海凯赛生物、深圳华大基因等企业集中签约了"生物基复合材料新 能源结构件研发制造项目"等5项"双招双引"重点项目， 累计投资达11.8亿元 。 其中，芜湖市三山经开区与 福莱 明生物 签约" 重组胶原蛋白和类胶原蛋白产品研发产业化项目 "；合肥市庐阳区与 华大基因 农业 签约" 华大生物农业 应用研究院建设和科技成果产业化项目 "； 安徽科宝生物 与中科院合肥物质研究院合作签约" 名贵中药材体培牛黄及其关键原料胆红素生物制造产业化 核心技术攻关 "项目，合肥高新区与 凯赛生物 签约" 生物基复合材料新能源结构件研发制造项目 "。 此外，由中国科学技术大学副校长周丛照、安徽师范大学常务副校长熊宇杰等专家学者发起的 安徽省合成生物学会 （筹）组建启动仪式也在当天举行。 资料来源： 添加微信请备注 ...

Summary of Kaisa Biotech Conference Call Company Overview - Kaisa Biotech reported a profit increase of 33.41% in 2024, reaching 489 million yuan, with a non-recurring net profit growth of 51.6% to 465 million yuan. [2][3] - In Q1 2025, the company achieved record revenue of 776 million yuan, a year-on-year increase of 13.33%, and a net profit of 137 million yuan, up 30.11%. [2][3] Financial Performance - For 2024, Kaisa Biotech's total revenue was 2.958 billion yuan, a 39.91% increase year-on-year, with a gross profit of 924 million yuan, up 51.83%. [3] - As of the end of 2024, total assets were 19.021 billion yuan, a 1% increase from the beginning of the year, and net assets were 11.507 billion yuan, up 3.07%. [3] - R&D investment was 233 million yuan, accounting for 7.89% of revenue, a decrease of 1 percentage point year-on-year. [3] Industry Dynamics - Approximately 40% of Kaisa Biotech's revenue comes from overseas markets, with limited impact from the US-China trade war due to the nature of its products. [2][6] - The company is focusing on large-scale applications in the construction sector through collaboration with China Merchants Group, with pilot projects underway in six regions. [2][7] Strategic Partnerships - Kaisa Biotech formed a joint venture with CATL (Contemporary Amperex Technology Co., Limited) named Anhui Kaixian Times, expected to involve new energy battery technologies and materials development. [2][8] - Multiple projects in power batteries and energy storage systems are being validated, with partial production expected by the second half of 2025. [9] Product Development - The company is launching a 10,000-ton bio-based polyamide project, which began production at the end of 2024 and has started sales in 2025, receiving positive customer feedback. [2][12] - Bio-based polyamide is being developed for various applications, including vulcanizing agents and agricultural intermediates, with a focus on increasing market share domestically and internationally. [13] R&D and Innovation - Kaisa Biotech is investing in AI through a partnership with Molecular Heart to enhance R&D efficiency in biomanufacturing, focusing on protein structure prediction and metabolic pathway design. [4][23] - The company has over 20 years of experience in the industrialization of long-chain dicarboxylic acids, utilizing gene editing and AI tools to accelerate R&D and reduce costs. [4][26] Market Outlook - The demand for long-chain dicarboxylic acids remains stable, with ongoing development of new applications expected to positively impact future demand. [29] - The company is also expanding its production capacity for long-chain dicarboxylic acids and related products to meet market needs. [21][29] Additional Insights - The joint venture with China Merchants is progressing, with equipment procurement nearly complete and construction expected to be operational by the end of 2025. [11] - The company is actively working on industry standard certifications to facilitate the adoption of its new materials in various applications. [28]

Core Viewpoint - The company, Shanghai Kaisa Biotechnology Co., Ltd., has released its quarterly report for the first quarter of 2025, ensuring the accuracy and completeness of the financial information presented [2][3]. Financial Data - The financial statements for the first quarter of 2025 have not been audited [3]. - The company reported a net profit of 0 yuan for the merged entity prior to the merger, consistent with the previous period [6]. Shareholder Information - The company has completed the registration of 137,911,755 new shares issued to specific investors as of March 31, 2025 [5]. Audit Opinion - The financial statements are categorized as unaudited, indicating that they have not undergone an external audit process [6].

Financial Performance - The company's revenue for Q1 2025 reached ¥775,769,935.75, representing a 13.33% increase compared to ¥684,521,536.95 in the same period last year[4] - Net profit attributable to shareholders was ¥136,950,113.57, a 30.11% increase from ¥105,258,699.94 year-on-year[4] - Net profit for Q1 2025 was CNY 124,318,691.92, compared to CNY 106,857,611.48 in Q1 2024, representing an increase of 16.25%[19] - The operating profit for Q1 2025 was CNY 161,685,700.77, up from CNY 123,463,826.25 in Q1 2024, indicating a growth of 30.93%[19] - Total revenue for Q1 2025 reached CNY 775,769,935.75, an increase of 13.38% compared to CNY 684,521,536.95 in Q1 2024[18] - Earnings per share for Q1 2025 were CNY 0.23, compared to CNY 0.18 in Q1 2024, marking a 27.78% increase[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 59.36% to ¥87,489,386.91, down from ¥215,276,527.96 in the previous year[4] - Cash received from sales and services in Q1 2025 was CNY 701,043,331.96, an increase from CNY 649,158,049.17 in Q1 2024, reflecting a growth of 7.99%[23] - Total cash outflow from operating activities was $657,274,979.57, an increase from $537,266,390.20 in the previous period[24] - Cash and cash equivalents at the end of the period totaled $10,635,851,218.02, up from $4,795,218,006.40 at the end of the previous period[25] - The net increase in cash and cash equivalents was $5,449,886,504.90, contrasting with a decrease of $218,561,556.52 in the prior period[25] Assets and Liabilities - Total assets increased by 29.80% to ¥24,689,868,403.18 from ¥19,021,477,349.64 at the end of the previous year[5] - The company's total liabilities decreased to RMB 3,161,806,107.54 from RMB 3,531,118,757.92, indicating a reduction of about 10.5%[16] - The total current liabilities decreased to RMB 2,538,495,884.89 from RMB 2,917,855,546.03, a reduction of about 13.0%[16] - The company's cash and cash equivalents increased significantly to RMB 10,797,271,252.93 from RMB 5,346,793,890.23, representing an increase of about 102.3%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,060[8] - The company's equity attributable to shareholders increased by 52.64% to ¥17,563,815,224.81 from ¥11,507,005,495.25[5] - Total equity attributable to shareholders increased from CNY 11,507,005,495.25 to CNY 17,563,815,224.81, a growth of 52.73%[17] Research and Development - R&D investment totaled ¥60,550,596.03, up 35.21% from ¥44,784,258.67, accounting for 7.81% of revenue[5] - Research and development expenses for Q1 2025 were CNY 60,550,596.03, compared to CNY 44,784,258.67 in Q1 2024, representing an increase of 35.25%[19] Other Financial Metrics - The weighted average return on equity rose to 1.18%, an increase of 0.24 percentage points from 0.94%[4] - The basic and diluted earnings per share were both ¥0.23, reflecting a 27.78% increase from ¥0.18[4] - Non-recurring gains and losses amounted to ¥1,587,608.51 for the period[6] - Other comprehensive income for Q1 2025 was CNY 3,862,477.80, compared to a loss of CNY 2,075,953.82 in Q1 2024, indicating a significant turnaround[20]

凯赛生物公告，2025年第一季度营收为7.76亿元，同比增长13.33%；净利润为1.37亿元，同比增长 30.11%。 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月21日晚间， 凯赛生物 发布2024年年度报告。报告期内，公司实现 营业收入29.58 亿元，比上年同期上升39.91% ， 实现营业利润 5.52 亿元，比上年 同期上升21.41% ；归属于上市公司股东的净利润 4.89 亿元，比上年同期上升33.41%。 | 单位 | | --- | | . | | 리 | | 市种 . | | 人民币 . | | | | | 本期比上年 | | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 同期增减 | 2022年 | | | | | (%) | | | 营业收入 | 2, 957, 911, 554. 76 | 2, 114, 174, 868. 81 | 39. 91 | 2, 441, 103, 971. 54 | | 归属于上市公 | | | | | | 司股东的净利 | 488, 961, 919. 11 | 366, 524, 3 ...

Core Insights - The company reported a revenue of 2.958 billion yuan in 2024, representing a year-on-year growth of 39.91%, and a net profit of 489 million yuan, up 33.41% year-on-year [2] - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares to all shareholders [2] Group 1: Business Performance - The company maintains a global leading position in long-chain dicarboxylic acid products, with significant sales growth driven by technological advancements and market expansion [2][3] - The production capacity of bio-based caprylic acid has significantly increased since the project commenced in Q3 2022, leading to improved operational rates and market share [3] - The company successfully launched a 10,000-ton bio-based piperidine project at the end of 2024, which has begun generating sales [3] Group 2: Strategic Developments - The company has entered into a strategic cooperation agreement with the Hefei government and China Merchants Group to leverage their strengths in policy guidance, application scenario development, and biomanufacturing technology innovation [4] - A new company focused on composite materials manufacturing has been established, and projects are accelerating in Hefei, indicating the establishment of a comprehensive industrial chain for bio-based materials [4] Group 3: Research and Development - The company plans to focus on the development of the bio-based polyamide market in 2025, with a factory for bio-based polyamide modification and Bio-PPA CFRT under construction in Hefei [5] - Research and development expenses for 2024 amounted to 233 million yuan, a year-on-year increase of 23.38%, accounting for 7.89% of total revenue, with significant progress in various R&D projects [5]